company background image
NXS

Next Science ASX:NXS Stock Report

Last Price

AU$1.01

Market Cap

AU$216.9m

7D

-6.5%

1Y

-32.0%

Updated

07 Aug, 2022

Data

Company Financials +
NXS fundamental analysis
Snowflake Score
Valuation4/6
Future Growth5/6
Past Performance0/6
Financial Health3/6
Dividends0/6

NXS Stock Overview

Next Science Limited, a medical technology company, researches, develops, and commercializes technologies that address the impacts of biofilms in human health in the United States and Australia.

Next Science Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Next Science
Historical stock prices
Current Share PriceAU$1.01
52 Week HighAU$1.55
52 Week LowAU$0.70
Beta0.81
1 Month Change22.42%
3 Month Change18.13%
1 Year Change-31.99%
3 Year Change-65.76%
5 Year Changen/a
Change since IPO-25.19%

Recent News & Updates

Shareholder Returns

NXSAU Medical EquipmentAU Market
7D-6.5%4.7%1.0%
1Y-32.0%-17.2%-7.9%

Return vs Industry: NXS underperformed the Australian Medical Equipment industry which returned -17.2% over the past year.

Return vs Market: NXS underperformed the Australian Market which returned -7.9% over the past year.

Price Volatility

Is NXS's price volatile compared to industry and market?
NXS volatility
NXS Average Weekly Movement11.5%
Medical Equipment Industry Average Movement11.5%
Market Average Movement10.6%
10% most volatile stocks in AU Market17.5%
10% least volatile stocks in AU Market4.7%

Stable Share Price: NXS is not significantly more volatile than the rest of Australian stocks over the past 3 months, typically moving +/- 12% a week.

Volatility Over Time: NXS's weekly volatility (12%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
2012n/aJudy Mitchellhttps://www.nextscience.com

Next Science Limited, a medical technology company, researches, develops, and commercializes technologies that address the impacts of biofilms in human health in the United States and Australia. The company develops its products using Xbio Technology platform. It offers SURGX, an antimicrobial gel designed for surgical infection management; BACTISURE, a wound lavage that is used to remove biofilm; BlastX, an antimicrobial wound gel that destroys bacteria within the gel and defends from recolonization while maintaining a moist wound environment; and XPERIENCE, an no rinse antimicrobial solution that helps prevent surgical site infections.

Next Science Fundamentals Summary

How do Next Science's earnings and revenue compare to its market cap?
NXS fundamental statistics
Market CapUS$149.55m
Earnings (TTM)-US$9.35m
Revenue (TTM)US$8.95m

16.7x

P/S Ratio

-16.0x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
NXS income statement (TTM)
RevenueUS$8.95m
Cost of RevenueUS$2.01m
Gross ProfitUS$6.94m
Other ExpensesUS$16.29m
Earnings-US$9.35m

Last Reported Earnings

Dec 31, 2021

Next Earnings Date

n/a

Earnings per share (EPS)-0.044
Gross Margin77.56%
Net Profit Margin-104.49%
Debt/Equity Ratio0%

How did NXS perform over the long term?

See historical performance and comparison
We’ve recently updated our valuation analysis.

Valuation

Is NXS undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

4/6

Valuation Score 4/6

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • Analyst Forecast

Key Valuation Metric

Which metric is best to use when looking at relative valuation for NXS?

Other financial metrics that can be useful for relative valuation.

NXS key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue16x
Enterprise Value/EBITDA-15.5x
PEG Ration/a

Price to Sales Ratio vs Peers

How does NXS's PS Ratio compare to its peers?

NXS PS Ratio vs Peers
The above table shows the PS ratio for NXS vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPSEstimated GrowthMarket Cap
Peer Average17.6x
SDI SDI
1.1xn/aAU$99.3m
PNV PolyNovo
36.5x36.1%AU$1.3b
NAN Nanosonics
12.1x15.3%AU$1.5b
OSX Osteopore
20.5xn/aAU$22.9m
NXS Next Science
16.7x51.9%AU$216.9m

Price-To-Sales vs Peers: NXS is good value based on its Price-To-Sales Ratio (16.7x) compared to the peer average (17.6x).


Price to Earnings Ratio vs Industry

How does NXS's PE Ratio compare vs other companies in the AU Medical Equipment Industry?

Price-To-Sales vs Industry: NXS is expensive based on its Price-To-Sales Ratio (16.7x) compared to the Australian Medical Equipment industry average (6.6x)


Price to Sales Ratio vs Fair Ratio

What is NXS's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

NXS PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio16.7x
Fair PS Ratio32.1x

Price-To-Sales vs Fair Ratio: NXS is good value based on its Price-To-Sales Ratio (16.7x) compared to the estimated Fair Price-To-Sales Ratio (32.1x).


Share Price vs Fair Value

What is the Fair Price of NXS when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: NXS (A$1.01) is trading below our estimate of fair value (A$8.85)

Significantly Below Fair Value: NXS is trading below fair value by more than 20%.


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Target price is more than 20% higher than the current share price, but there are not enough analysts covering the stock to determine statistical confidence in agreement.


Discover undervalued companies

Future Growth

How is Next Science forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?

Future Growth Score

5/6

Future Growth Score 5/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


95.5%

Forecasted annual earnings growth

Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: NXS is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (1.8%).

Earnings vs Market: NXS is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: NXS is expected to become profitable in the next 3 years.

Revenue vs Market: NXS's revenue (51.9% per year) is forecast to grow faster than the Australian market (5.7% per year).

High Growth Revenue: NXS's revenue (51.9% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: NXS's Return on Equity is forecast to be low in 3 years time (18.8%).


Discover growth companies

Past Performance

How has Next Science performed over the past 5 years?

Past Performance Score

0/6

Past Performance Score 0/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


-8.7%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: NXS is currently unprofitable.

Growing Profit Margin: NXS is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: NXS is unprofitable, and losses have increased over the past 5 years at a rate of 8.7% per year.

Accelerating Growth: Unable to compare NXS's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: NXS is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (32.6%).


Return on Equity

High ROE: NXS has a negative Return on Equity (-86.84%), as it is currently unprofitable.


Discover strong past performing companies

Financial Health

How is Next Science's financial position?

Financial Health Score

3/6

Financial Health Score 3/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Stable Cash Runway

  • Forecast Cash Runway

Financial Position Analysis

Short Term Liabilities: NXS's short term assets ($10.2M) exceed its short term liabilities ($1.5M).

Long Term Liabilities: NXS's short term assets ($10.2M) exceed its long term liabilities ($1.4M).


Debt to Equity History and Analysis

Debt Level: NXS has more cash than its total debt.

Reducing Debt: Insufficient data to determine if NXS's debt to equity ratio has reduced over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: NXS has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: Insufficient data to determine if NXS has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.


Discover healthy companies

Dividend

What is Next Science current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Cash Flow Coverage

Dividend Yield vs Market

Notable Dividend: Unable to evaluate NXS's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate NXS's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if NXS's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if NXS's dividend payments have been increasing.


Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as NXS has not reported any payouts.


Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?

4.2yrs

Average management tenure


CEO

Judy Mitchell

5yrs

Tenure

US$202,775

Compensation

Ms. Judith Mitchell, also known as Judy, M.B.A, serves as Managing Director and Chief Executive Officer of Next Science Limited since August 2017 and serves as its Executive Director since October 20, 2017...


CEO Compensation Analysis

Compensation vs Market: Judy's total compensation ($USD202.78K) is about average for companies of similar size in the Australian market ($USD279.73K).

Compensation vs Earnings: Judy's compensation has been consistent with company performance over the past year.


Leadership Team

Experienced Management: NXS's management team is considered experienced (4.2 years average tenure).


Board Members

Experienced Board: NXS's board of directors are considered experienced (4.8 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 8.5%.


Top Shareholders

Company Information

Next Science Limited's employee growth, exchange listings and data sources


Key Information

  • Name: Next Science Limited
  • Ticker: NXS
  • Exchange: ASX
  • Founded: 2012
  • Industry: Health Care Supplies
  • Sector: Healthcare
  • Implied Market Cap: AU$216.938m
  • Shares outstanding: 214.79m
  • Website: https://www.nextscience.com

Location

  • Next Science Limited
  • The Zenith Building, Tower A
  • Suite 1902
  • Chatswood
  • New South Wales
  • 2067
  • Australia

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/08/07 00:00
End of Day Share Price2022/08/05 00:00
Earnings2021/12/31
Annual Earnings2021/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.